Literature DB >> 12902345

The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.

Boulbaba Selmi1, Jerome Deval, Karine Alvarez, Joelle Boretto, Simon Sarfati, Catherine Guerreiro, Bruno Canard.   

Abstract

Resistance to zidovudine (3'-azido-3'-deoxythymidine, AZT) by the human immunodeficiency virus, type 1, requires multiple amino acid substitutions such as D67N/K70R/T215F/K219Q in the viral reverse transcriptase (RT). In this background of AZT resistance, additional "suppressive" substitutions such as Y181C restore sensitivity to AZT. In order to characterize the mechanism of this AZT resistance suppression, the Y181C substitution was introduced into both wild-type and AZT-resistant reverse transcriptase. The introduction of the Y181C substitution suppresses the increased repair (or unblocking) of the AZTMP-terminated primer provided by the AZT resistance substitutions in RT using either DNA or RNA templates, independently from the RT RNase H activity. Contrary to wild-type RT, the low level of unblocking activity is not due to inhibition by the next correct nucleotide binding to the RT/AZTMP-terminated primer complex. When Y181C is added to the AZT resistance substitutions, ATP binds with less affinity to the AZTMP-terminated primer-RT binary complex. These results provide an insight into one possible molecular mechanism of re-sensitization of AZT-resistant viruses by suppressive substitutions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902345     DOI: 10.1074/jbc.M302928200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Authors:  Atsuko Hachiya; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Xiongying Tu; Krzysztof Palczewski; Yee Tsuey Ong; Zhe Li; Daniel T Griffin; Matthew M Schuckmann; Junko Tanuma; Shinichi Oka; Kamalendra Singh; Eiichi N Kodama; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2012-07-02       Impact factor: 5.157

2.  Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

Authors:  Christine E Koval; Carrie Dykes; Jiong Wang; Lisa M Demeter
Journal:  Virology       Date:  2006-06-21       Impact factor: 3.616

3.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.

Authors:  Hong-Tao Xu; Maureen Oliveira; Eugene L Asahchop; Matthew McCallum; Peter K Quashie; Yingshan Han; Yudong Quan; Mark A Wainberg
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

5.  Structural basis of HIV-1 resistance to AZT by excision.

Authors:  Xiongying Tu; Kalyan Das; Qianwei Han; Joseph D Bauman; Arthur D Clark; Xiaorong Hou; Yulia V Frenkel; Barbara L Gaffney; Roger A Jones; Paul L Boyer; Stephen H Hughes; Stefan G Sarafianos; Eddy Arnold
Journal:  Nat Struct Mol Biol       Date:  2010-09-19       Impact factor: 15.369

6.  Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.

Authors:  Zixin Hu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

7.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

8.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

Review 9.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090

10.  Bayesian network analyses of resistance pathways against efavirenz and nevirapine.

Authors:  Koen Deforche; Ricardo J Camacho; Zehave Grossman; Marcelo A Soares; Kristel Van Laethem; David A Katzenstein; P Richard Harrigan; Rami Kantor; Robert Shafer; Anne-Mieke Vandamme
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.